Managing type 1 diabetes has become more precise and less burdensome thanks to the CamAPS FX, an advanced Automated Insulin Delivery (AID) system developed by CamDiab Ltd. With its innovative algorithm and seamless integration of CGM and insulin pump technologies, the CamAPS FX is designed to improve glucose control while simplifying diabetes management.
What Is the CamAPS FX System?
The CamAPS FX is a state-of-the-art AID system that automatically adjusts insulin delivery based on real-time glucose readings. Developed by CamDiab Ltd., a leader in diabetes technology, the system represents decades of research and development to enhance the lives of people with diabetes.
Specifications
- Size and Weight: The CamAPS FX system runs as an app on an Android smartphone, meaning its physical size and weight depend on the user’s device.
- Cartridge Size: Compatible insulin pumps can hold up to 300 units of insulin.
- Basal Rates: Fully customizable to individual needs, ensuring precise delivery.
- Bolus Delivery: Boluses can be administered manually through the app, with increments tailored to the user’s preferences.
- Water Resistance: This varies depending on the insulin pump and CGM models used.
How Does It Work?
The CamAPS FX uses a model predictive control algorithm to analyze Continuous Glucose Monitor (CGM) data. It adjusts basal insulin delivery every 8–12 minutes based on CGM readings received every 5 minutes. This adaptive system ensures precise and responsive insulin dosing, helping users maintain optimal glucose levels throughout the day.
The Algorithm Behind the Technology
The CamAPS FX algorithm was developed at the University of Cambridge. With years of refinement, it adapts to each user’s unique needs, making it suitable for a wide range of individuals, including young children and pregnant women with type 1 diabetes.
Target Glucose Levels
The system’s default target glucose level is 5.8 mmol/L (104 mg/dL). Users can personalize their target range from 4.4 mmol/L to 11.0 mmol/L (79 mg/dL to 198 mg/dL), offering flexibility to suit different lifestyles and clinical needs.
Regulatory Approval
The CamAPS FX received FDA clearance in May 2024 for use in individuals aged two years and older, including during pregnancy. This approval reflects the system’s safety and effectiveness in managing diabetes across diverse populations.
Cost and Insurance
The cost of the CamAPS FX system depends on factors such as insurance coverage and regional availability. Consulting with healthcare providers and insurance companies is recommended to determine specific pricing and coverage details.
What’s Included?
The CamAPS FX system includes:
- The CamAPS FX app, compatible with Android devices
- A CGM, such as the Dexcom G6 or FreeStyle Libre 3
- A compatible insulin pump, including the Dana RS, Dana-i, and mylife YpsoPump. Comprehensive training ensures users understand how to use the system effectively.
Mobile Application and Remote Access
The CamAPS FX app allows users to:
- Administer bolus doses
- View CGM data in real-time
- Adjust basal and bolus settings
Data can also be shared with healthcare providers via platforms like Glooko XT, enabling remote monitoring and personalized care.
Battery Maintenance
Battery requirements depend on the insulin pump and CGM devices used with the system. Users should refer to the respective manuals for details about charging and maintenance.
Pros and Cons
Pros:
- Adaptive algorithm that personalizes insulin delivery in real-time
- Compatibility with multiple CGMs and insulin pumps
- Approved for young children and during pregnancy
Cons:
- Only compatible with Android smartphones
- Availability may vary by region
Conclusion
The CamAPS FX system offers a powerful and flexible solution for individuals managing type 1 diabetes. Its adaptive algorithm, compatibility with various devices, and user-friendly app make it a standout choice for people seeking better glucose control with less daily effort. To learn more, visit CamDiab’s official website or consult your healthcare provider.